PRM63 Modelling the Adenoma and Serrated Pathway to Colorectal Cancer (ASCCA)  by Greuter, M.J. et al.
A586  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: In developing probabilistic models to analyse cost-effectiveness, it 
is possible to control many model parameters using random seeds so that output 
differences should be due to the interventions being modelled rather than due to 
chance differences in the model parameters. However, at the point of intervention, 
the simulated patient effectively enters a parallel universe where outcomes may 
legitimately be better or worse irrespective of the intervention. The purpose of this 
study was to present an example of reduced health outcomes contrary to expec-
tation. MethOds: Using a model developed to evaluate the impact of different 
MRI-based breast cancer surveillance strategies, the total benefits measured for 
individual simulated patients were compared between surveillance and no sur-
veillance. Random seeds were used to ensure model parameters were matched 
between different model runs. Model structure ensured that later detection of 
cancer could not be associated with a better outcome. For breast cancer occur-
rence, random seeds were matched until the first incidence. Individuals could 
have multiple cancers. Results: Across 7 surveillance strategies, compared to a 
situation of no surveillance, life expectancy was unchanged for between 97.7% 
and 99.0% of individuals. Depending on the surveillance strategy, between 0.98% 
and 2.2% of individuals had increased life expectancy, and between 0.04% and 
0.1% of simulated individuals experienced a reduced life expectancy. A larger 
number of individuals had reduced life expectancy due to surveillance, but this is 
attributable to the detection of DCIS which does not always develop into invasive 
cancer. cOnclusiOns: When comparing interventions using probabilistic models, 
chance variation can result in poorer outcomes despite the intervention. Although 
these anomalies are not apparent in summary figures as there may be an “on aver-
age” benefit, their occurrence is legitimate and should not be artificially prevented.
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Objectives: Previous research has demonstrated wide varieties in modelling 
methods of pharmacoeconomic (PE) studies focussing on biological drugs for the 
treatment of rheumatoid arthritis (RA). To eradicate this variety, disease specific 
guidelines were presented in 2002 by OMERACT-ILAC. The objective of this study 
is to assess whether recently published PE studies adhered to these recommen-
dations. MethOds: A literature review was conducted for PE studies evaluating 
TNF-α inhibitors use in RA. Four different databases (e.g. Embase, NIHR-EED) were 
searched for PE studies published that focus on Adalimumab between October 
2003 and May 2013. Methodological quality of included studies was checked 
against the CHEC-checklist. Data extraction forms were used to retrieve informa-
tion such as study outcomes (QALY’s, costs, ICER) and modelling methods and 
parameters (e.g. time horizon, sources for costs and effectiveness data). Finally, 
information retrieved from all studies was compared to recommendations pro-
posed by the OMERACT-ILAR guideline to assess adherence to these recommenda-
tions. Results: Nine studies were identified that met all inclusion criteria and 
were included in our analysis. All studies met at least 12 of the 19 items of the 
CHEC checklist for quality and 3 studies met all 19 items. Study outcomes varied 
considerably in QALY’s calculated, costs and ICER’s. Patient subtypes, modelling 
methods, sources for cost and effectiveness data also varied significantly. Only 
2 of the 12 recommendations published in the OMERACT-ILAR guideline were 
unanimously implemented in all 9 studies of our review. Only 1 study was found 
to contain all elements of guideline recommendations, albeit with some limita-
tions cOnclusiOns: We demonstrate that modelling methods still widely differ 
and adherence to disease-specific guidelines for the conduct of PE studies in RA is 
very low. Development of strict disease-specific guidelines in RA and subsequent 
adoption by re-imbursement agencies is vital to ensure comparability,validity and 
credibility of future PE studies.
PRM67
Modeling A switch fRoM tRivAlent to QuAdRivAlent influenzA 
vAccine in cAnAdA And the united KingdoM
Thommes E.W.1, Ismaila A.2, Meier G.3, Bauch C.T.4
1GlaxoSmithKline Canada, Mississauga, ON, Canada, 2GlaxoSmithKline, Mississauga, ON, 
Canada, 3GlaxoSmithKline Vaccines, Wavre, Belgium, 4University of Guelph, Guelph, ON, Canada
Objectives: Current trivalent influenza vaccines (TIVs) contain only one of the 
two currently circulating influenza B lineages (Victoria and Yamagata). Worldwide, 
in about half of all influenza seasons since co-circulation of the two B lineages 
commenced, the dominant B lineage did not match the one chosen for inclusion in 
the TIV. Quadrivalent influenza vaccines (QIVs) would help address this problem by 
including both B lineages each season. We modeled the impact of a country-wide 
switch from TIV to QIV on the yearly population-wide rates of influenza cases and 
influenza-associated events, in both Canada and the UK. MethOds: We calculated 
projections using a dynamic transmission model which incorporates four interact-
ing influenza strains, transmission-rate seasonality and age-specific mixing within 
the population, run over a 40-year time horizon. Influenza vaccine coverage rates in 
Canada and the UK were taken from public sources, TIV efficacy was obtained from 
a meta-analysis (Tricco et al., in press), and QIV efficacy was assumed to be similar 
to TIV without B lineage mismatch. Results: Across Canada, the model estimates 
that a switch from TIV to QIV would, in an average influenza season, avert 9% (rela-
tive) of influenza cases (= 237,000 cases), 9% (= 86,000) of general practitioner (GP) 
visits, 9% (= 12,000) of emergency room (ER) visits, 8% (= 2,500) of hospitalizations, 
and 7% (= 330) of deaths. Across the UK, the model estimates that 0.7% (= 70,000) 
of influenza cases, 0.8% (= 19,000) of GP visits, 0.8% (= 600) of ER visits, 0.8% (= 800) 
of hospitalizations, and 3% (= 270) of deaths would be averted. cOnclusiOns: In 
both Canada and the UK, a country-wide TIV-QIV switch is predicted to bring about 
a clear reduction in the burden of influenza. The relatively greater impact of the 
switch in Canada is due principally to that country’s higher vaccine uptake among 
people younger than 65 years.
simulation model of type 2 diabetes, based on the UKPDS 68 outcomes equations, 
was executed with and without the application of antithetic variates. The impact 
of the technique was evaluated through comparison of total cost and benefit esti-
mates, predicted over a long-term horizon of 40 years. Results: An approximate 
four-fold reduction was observed in the Monte Carlo Error (MCE) associated with 
estimated mean incremental costs and benefits, when antithetic variates were 
applied over 1,000 simulations of 1,000 individuals. For a fixed number of runs 
(1,000), the number of replicated individuals required to achieve 99% accuracy 
(MCE/mean< 1%) in incremental cost and benefit estimates fell from approximately 
500 and 550 respectively, to fewer than 50 with antithetic variates. Similarly, for 
a fixed cohort size (1,000) the same level of precision was produced with fewer 
than 10% of the simulation runs required otherwise. cOnclusiOns: The use 
of antithetic variates can improve the precision of modelling output; reducing 
the number of simulation runs and thus computation time required to perform 
analyses. The use of such variance reduction techniques should be pursued in the 
simulation of chronic conditions, as a means of achieving manageable run times 
and facilitating the extensive scenario and sensitivity analyses required as part 
of economic evaluations.
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Objectives: Most models developed for colorectal cancer (CRC) screening evalua-
tions are based on the adenoma-carcinoma pathway only. Currently, there is increas-
ing evidence that serrated lesions can also develop into CRC. This study aimed to 
develop a model that reflects both the adenoma-carcinoma pathway and the ser-
rated pathway to CRC and that includes characteristics of polyps. MethOds: The 
Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model was built using 
the scientific literature, expert opinion, data from the Dutch COCOS trial and Dutch 
cancer registry data. A flexible model structure was chosen to examine the impact 
of two alternative natural history assumptions: (i) all CRCs arise from adenomas and 
(ii) 15% of CRCs arise from serrated lesions. The two model versions were calibrated 
manually using a systematic, step-by-step approach. Results: Calibration resulted 
in 19 parameter sets for the adenoma-carcinoma pathway and 13 for the serrated 
pathway, matching the age- and sex-specific adenoma and serrated lesion prevalence 
in the COCOS trial and several other intermediate model outcomes. For the first natu-
ral history assumption, progression rates from advanced adenoma to CRC between 
1.6% and 2.7% were found to produce model-based age-standardized incidence rates 
within the 95% confidence interval of the Dutch incidence in 2009. For the second 
assumption, these progression rates were between 1.3% and 2.2%. Mean duration 
from adenoma to CRC was 24 years. cOnclusiOns: The ASCCA model will be used 
to evaluate the (cost-)effectiveness of different screening and surveillance strategies 
for CRC. Future analyses will evaluate the upcoming Dutch screening program using 
the two calibrated model versions. The implication of different test accuracies for 
different types of polyps with their characteristics can be taken into account in a 
straightforward manner. Furthermore, the impact of structural as well as parametric 
assumptions concerning the serrated pathway can be addressed.
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Objectives: Markov models are commonly used to study time dependent disease 
progression. While most models are cohort based, due to their limitation of dealing 
with heterogeneities, continuous variables, and dynamic strategies, individual-based 
microsimulation is being increasingly used. The objective was to compare microsimu-
lation to cohort approach in modeling COPD, while validating the two approaches 
against findings from TORCH trial. MethOds: We developed both models to study 
COPD progression in a cohort defined by the characteristics of TORCH patients. The 
microsimulation randomly generated a large number of patients and tracked each 
patient’s the lung function (FEV1), exacerbations, and mortality, based on individual’s 
characteristics and disease history. The cohort model included four COPD stages 
and death; it modeled exacerbations as events, assuming no impact on transitions 
or future exacerbations. Both models were populated by published data and results 
were compared against TORCH findings. Results: The mean decline in FEV1 over 
3-year was 126 ml in microsimulation, 49 ml in cohort model, compared to 117 ml in 
TORCH. The annual rates of moderate and severe exacerbations were 0.94 and 0.18 in 
microsimulation, 1.12 and 0.18 in cohort model, compared to 1.13 and 0.19 in TORCH. 
The 3-year mortality was 17.4% in microsimulation, 12.2% in cohort model, and 15.2% 
in TORCH. Microsimulation required simulating at least 3500 patients to obtain stable 
estimates, which took 4 minutes to run each scenario. It would take 300 hours to 
run 5000 scenarios for sensitivity analysis, while the cohort model took less than 1 
minute. cOnclusiOns: In COPD, patient heterogeneity and disease history can be 
conveniently captured in microsimulation, while parameter uncertainties are easily 
assessed using cohort approach. The cohort approach is simple to develop, but its 
inherent Markovian property cannot fully represent COPD pathology. Microsimulation 
is flexible in mimicking COPD progression, but it is computational expensive.
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